{"id":913836,"date":"2025-11-25T17:01:59","date_gmt":"2025-11-25T22:01:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\/"},"modified":"2025-11-25T17:01:59","modified_gmt":"2025-11-25T22:01:59","slug":"moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\/","title":{"rendered":"MoonLake Immunotherapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before December 15, 2025 to Discuss Your Rights \u2013 MLTX"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, Nov.  25, 2025  (GLOBE NEWSWIRE) &#8212; Levi &amp; Korsinsky, LLP notifies investors in\u00a0<strong>MoonLake Immunotherapeutics<\/strong> (&#8220;MoonLake&#8221; or the &#8220;Company&#8221;) (NASDAQ: MLTX) of a class action securities lawsuit.<\/p>\n<p>\n        <strong>CLASS DEFINITION: <\/strong>The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team:<\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-zn1RBLf0GeRKoAnuFXNWUdZ-YQJU_GhX7w-Chm9jugBkkjV-4MIYyV65maRwnSZFAvzj6MTh7TGS8IJqvITE3k70E9e7-7iCRr838Q7lCqezNVuvtWlcxPMjegoYVzztngpTr9lE4kmotz-cFSbQ8hV7zr9ao9wVIlqix-mjMnc3KtkSD70r7Tz6qgIzqvuqwKOBiCtnIgZKdHMrOtCwTL5ghnUGioGD6OzZWkJ5iXlMXa-TicP7OywEyT1RR2n\" rel=\"nofollow\" target=\"_blank\">https:\/\/zlk.com\/pslra-1\/moonlake-lawsuit-submission-form?prid=178920&amp;wire=3<\/a>\n      <\/p>\n<p>\n        <strong>MLTX<\/strong> investors may also contact Joseph E. Levi, Esq. via email at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=m5c9_Gqv-7Q1BnKT4OUKdM2HqImdM9JWDsnt6BQcoZztMXUB3iJ5vvM-iT10A5bNJyKbrhzqAFRBQ-vtEpNGZCusMVC5aEA0-CIy-oa-FgQ=\" rel=\"nofollow\" target=\"_blank\">jlevi@levikorsinsky.com<\/a>\u00a0or by telephone at (212) 363-7500.<\/p>\n<p>\n        <strong>CASE DETAILS: <\/strong>The filed complaint alleges that defendants made false statements and\/or concealed that: (1) It&#8217;s sole drug candidate, SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) SLK\u2019s distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; (3) SLK\u2019s distinct Nanobody structure supposed increased tissue penetration would not translate to clinical efficacy; and (4) based on the foregoing, defendants lacked a reasonable basis for their positive statements regarding SLK\u2019s purported superiority to monoclonal antibodies.<\/p>\n<p>\n        <strong>WHAT&#8217;S NEXT? <\/strong>If you suffered a loss in MoonLake during the relevant time frame, you have until <strong>December 15, 2025<\/strong>\u00a0to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn&#8217;t require that you serve as a lead plaintiff.<\/p>\n<p>\n        <strong>NO COST TO YOU: <\/strong>If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. <strong>There is no cost or obligation to participate.<\/strong><\/p>\n<p>\n        <strong>WHY LEVI &amp; KORSINSKY: <\/strong>Over the past 20 years, the team at Levi &amp; Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services\u2019 Top 50 Report as one of the top securities litigation firms in the United States.<\/p>\n<p>\n        <strong>CONTACT:<\/strong><br \/>\n        <br \/>Levi &amp; Korsinsky, LLP <br \/>Joseph E. Levi, Esq.<br \/>Ed Korsinsky, Esq.<br \/>33 Whitehall Street, 27th Floor<br \/>New York, NY 10004<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=m5c9_Gqv-7Q1BnKT4OUKdM2HqImdM9JWDsnt6BQcoZwBzWh1gTIoCDzGhWO0aLD_xBBe-Phm4evxsi3SdDDm_KzP3pKgJt3WCEI4W7coxoc=\" rel=\"nofollow\" target=\"_blank\">jlevi@levikorsinsky.com<\/a><br \/>Tel: (212) 363-7500<br \/>Fax: (212) 363-7171<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=doRHUGPN3-EiwP3Q8USWCjQdjzh3ip9_o9e8JqD2e7uG2VyoI_7Q5w9DCGfrPBLtN9tWLI5NpD0lFUfES393Kw==\" rel=\"nofollow\" target=\"_blank\">www.zlk.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MTY0NSM3MjkwOTc5IzIwMjA0MjY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2E2ZGY4ZDItNWQzNS00NTQ3LTgyMDUtNDBmNDRiODM0ZTI0LTEwMzIyOTMtMjAyNS0xMS0yNS1lbg==\/tiny\/Levi-Korsinsky-LLP.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) &#8212; Levi &amp; Korsinsky, LLP notifies investors in\u00a0MoonLake Immunotherapeutics (&#8220;MoonLake&#8221; or the &#8220;Company&#8221;) (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/moonlake-lawsuit-submission-form?prid=178920&amp;wire=3 MLTX investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (1) It&#8217;s sole drug candidate, SLK and BIMZELX share the same molecular targets (the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MoonLake Immunotherapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before December 15, 2025 to Discuss Your Rights \u2013 MLTX&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-913836","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MoonLake Immunotherapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before December 15, 2025 to Discuss Your Rights \u2013 MLTX - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MoonLake Immunotherapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before December 15, 2025 to Discuss Your Rights \u2013 MLTX - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) &#8212; Levi &amp; Korsinsky, LLP notifies investors in\u00a0MoonLake Immunotherapeutics (&#8220;MoonLake&#8221; or the &#8220;Company&#8221;) (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/moonlake-lawsuit-submission-form?prid=178920&amp;wire=3 MLTX investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (1) It&#8217;s sole drug candidate, SLK and BIMZELX share the same molecular targets (the &hellip; Continue reading &quot;MoonLake Immunotherapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before December 15, 2025 to Discuss Your Rights \u2013 MLTX&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-25T22:01:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MTY0NSM3MjkwOTc5IzIwMjA0MjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MoonLake Immunotherapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before December 15, 2025 to Discuss Your Rights \u2013 MLTX\",\"datePublished\":\"2025-11-25T22:01:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\\\/\"},\"wordCount\":396,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MTY0NSM3MjkwOTc5IzIwMjA0MjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\\\/\",\"name\":\"MoonLake Immunotherapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before December 15, 2025 to Discuss Your Rights \u2013 MLTX - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MTY0NSM3MjkwOTc5IzIwMjA0MjY=\",\"datePublished\":\"2025-11-25T22:01:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MTY0NSM3MjkwOTc5IzIwMjA0MjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MTY0NSM3MjkwOTc5IzIwMjA0MjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MoonLake Immunotherapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before December 15, 2025 to Discuss Your Rights \u2013 MLTX\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MoonLake Immunotherapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before December 15, 2025 to Discuss Your Rights \u2013 MLTX - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\/","og_locale":"en_US","og_type":"article","og_title":"MoonLake Immunotherapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before December 15, 2025 to Discuss Your Rights \u2013 MLTX - Market Newsdesk","og_description":"NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) &#8212; Levi &amp; Korsinsky, LLP notifies investors in\u00a0MoonLake Immunotherapeutics (&#8220;MoonLake&#8221; or the &#8220;Company&#8221;) (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/moonlake-lawsuit-submission-form?prid=178920&amp;wire=3 MLTX investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (1) It&#8217;s sole drug candidate, SLK and BIMZELX share the same molecular targets (the &hellip; Continue reading \"MoonLake Immunotherapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before December 15, 2025 to Discuss Your Rights \u2013 MLTX\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-25T22:01:59+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MTY0NSM3MjkwOTc5IzIwMjA0MjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MoonLake Immunotherapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before December 15, 2025 to Discuss Your Rights \u2013 MLTX","datePublished":"2025-11-25T22:01:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\/"},"wordCount":396,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MTY0NSM3MjkwOTc5IzIwMjA0MjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\/","name":"MoonLake Immunotherapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before December 15, 2025 to Discuss Your Rights \u2013 MLTX - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MTY0NSM3MjkwOTc5IzIwMjA0MjY=","datePublished":"2025-11-25T22:01:59+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MTY0NSM3MjkwOTc5IzIwMjA0MjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MTY0NSM3MjkwOTc5IzIwMjA0MjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moonlake-immunotherapeutics-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-december-15-2025-to-discuss-your-rights-mltx-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MoonLake Immunotherapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before December 15, 2025 to Discuss Your Rights \u2013 MLTX"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/913836","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=913836"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/913836\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=913836"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=913836"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=913836"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}